Remaining questions after ASCO include whether Lumakras (sotorasib) might work in first-line NSCLC with certain co-mutations and if ocular toxicities will hamper bemarituzumab in gastric cancer.

The firms hope academic research can yield first-in-class therapies and spinout companies. Also, Yale unveils research alliances with three biotechs.

Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.

iTeos presents early anti-TIGIT results, Affimed reports 100% response rate in Hodgkin lymphoma, Treovir will start a pivotal Phase II after Phase I pediatric glioma study, updates in KRAS-mutated cancers from Revolution Medicines and Cardiff Oncology, plus Opdivo plus chemo shows complete responses in neoadjuvant lung cancer and Lilly’s Retevmo is active in additional tumors.